The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.y

Progression, acceleration or exacerbation of preexisting ILD/fibrosis

Exacerbation ob underlying IPF, was deemed unrelated to the drug in the paper by Ikeda et al., because rechallenge with the drug did not lead to relapse of the exacerbation in the patient

Generally-speaking, evidence for nintedanib-induced ILD is low-to-very low

Publications

Yonezawa T, Nishizaki S, Kako H, Amano H, Murao H, Fukami M, Ogisu T, Katano T, Ito S

[A CASE OF IDIOPATHIC PULMONARY FIBROSIS WITH SUSPECTED DRUG-INDUCED LUNG INJURY FOLLOWING ACUTE EXACERBATION AFTER NINTEDANIB ADMINISTRATION].

Arerugi = [Allergy]. 2025;74(2):83-88

Ikeda S, Sekine A, Baba T, Yamakawa H, Morita M, Kitamura H, Ogura T

Administration of nintedanib after discontinuation for acute exacerbation of idiopathic pulmonary fibrosis: a case report.

BMC pulmonary medicine. 2016;16:38